» Articles » PMID: 12516098

The Patched Polymorphism Pro1315Leu (C3944T) May Modulate the Association Between Use of Oral Contraceptives and Breast Cancer Risk

Overview
Journal Int J Cancer
Specialty Oncology
Date 2003 Jan 8
PMID 12516098
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

The gene coding for the human homologue of the Drosophila segment polarity gene patched (PTCH1) is mutated in several common human tumors. In mice, haplodeficiency at the Ptch1 locus results in severe histologic defects in mammary ductal structure. We found no mutations within the coding region of PTCH1 in 17 human primary breast carcinomas. However, the biallelic Pro1315Leu (C3944T) polymorphism of PTCH1 was significantly associated with breast cancer in 41 Bavarian patients compared to 85 healthy controls. We investigated whether this variant influences susceptibility for breast cancer in 611 breast cancer patients diagnosed by age 50 years and 1,057 controls matched by age and study region in Germany and in 1,093 breast cancer patients from the United Kingdom. Allele and genotype frequencies were not different between cases and controls. However, multivariate logistic regression analysis revealed an effect modification of oral contraceptive use (OC) on breast cancer risk by Leu-carrier status. Compared to women who have Pro/Pro and never used OC, Pro/Pro OC users had an increased odds ratio for breast cancer of 1.7. The odds ratio was also 1.7 for Leu-carriers who never used OC, but this was attenuated among Leu-carriers who ever used OC by 20%. The gene-environmental interaction was confirmed in case-only analysis of the German and British studies, yielding an interaction odds ratio of 0.7 for premenopausal women (p = 0.06). Longer duration of pill use was associated with a significantly greater risk reduction (p for trend = 0.015). Our novel observation of a differential effect of OC use on breast cancer risk by PTCH1 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched (SHH/PTCH1) signaling pathway being involved in hormone-induced development of breast carcinoma.

Citing Articles

Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy.

Utpal B, Dehbia Z, Zidan B, Sweilam S, Singh L, Arunkumar M Med Oncol. 2024; 42(1):4.

PMID: 39549201 DOI: 10.1007/s12032-024-02551-x.


PTCH1 gene variants rs357564, rs2236405, rs2297086 and rs41313327, mRNA and tissue expression in basal cell carcinoma patients from Western Mexico.

Zambrano-Roman M, Padilla-Gutierrez J, Valle Y, Munoz-Valle J, Guevara-Gutierrez E, Martinez-Fernandez D J Clin Lab Anal. 2024; 38(3):e25010.

PMID: 38287479 PMC: 10873687. DOI: 10.1002/jcla.25010.


Sex disparity in skin carcinogenesis and potential influence of sex hormones.

Collier V, Musicante M, Patel T, Liu-Smith F Skin Health Dis. 2022; 1(2):e27.

PMID: 35664979 PMC: 9060035. DOI: 10.1002/ski2.27.


Novel PTCH1 mutations in Japanese familial nevoid basal cell carcinoma syndrome.

Nakase Y, Hamada A, Kitamura N, Hata T, Toratani S, Yamamoto T Hum Genome Var. 2020; 7(1):38.

PMID: 33298892 PMC: 7674431. DOI: 10.1038/s41439-020-00126-6.


Gli2 mediates the development of castration‑resistant prostate cancer.

Xia L, Bouamar H, Gu X, Zeballos C, Qin T, Wang B Int J Oncol. 2020; 57(1):100-112.

PMID: 32319599 PMC: 7252461. DOI: 10.3892/ijo.2020.5044.